Latest Cancer immunotherapy Stories
AMES, Iowa, Oct. 2, 2012 /PRNewswire/ -- NewLink Genetics (NASDAQ:NLNK) today announced that the company will be presenting at the 3(rd) Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in New York. Dr. Charles Link, NewLink's Chairman and Chief Executive Officer, will provide an overview of NewLink. The presentation is expected to begin at 3:45pm ET. Dr. Link...
SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapies to treat solid tumor cancers, announced today that the company will be presenting at the 3(rd) Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in New York. (Logo:...
SAN DIEGO, Sept. 20, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the following healthcare and investor conferences in upcoming weeks: Noble Financial BioXposition (BIOX), University of Connecticut, Stamford Campus, Stamford, CT, September 24 at 4:00 PM ET MD Becker...
TUEBINGEN, Germany, July 29, 2012 /PRNewswire/ -- Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC) IMA901 is currently being evaluated in a pivotal phase 3 randomized study in patients with RCC immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of...
MAINZ, Germany and NEW YORK, July 26, 2012 /PRNewswire/ -- Increasing transparency and quality of immune response measurements The Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP) and the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute (CRI) today announced the publication of a letter in Immunity discussing the results of an unique vetting process that involved multiple international groups and individuals and has...
Northwestern Brain Tumor Institute participates in national glioblastoma clinical trial CHICAGO, July 24, 2012 /PRNewswire-USNewswire/ -- Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor. The trial is studying the vaccine's effect on glioblastoma multiformes (GBM), the most common and aggressive type of primary brain tumor. The trial is an example of a...
Cancers are notorious for secreting chemicals that confuse the immune system and thwarting biological defenses. To counter that effect, some cancer treatments try to neutralize the cancer's chemical arsenal and boost a patient's immune response--though attempts to do both at the same time are rarely successful. Now, researchers have developed a novel system to simultaneously deliver a sustained dose of both an immune-system booster and a chemical to counter the cancer's secretions,...
AMSTERDAM, June 15, 2012 /PRNewswire/ -- Dr Alan Ramsay will present findings of a study in patients with Chronic Lymphocytic Leukemia that will contribute to the design of immunotherapeutic strategies leading to the killing of cancer cells at the 17th Congress of the European Hematology Association in Amsterdam. T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells. T cell activity is tightly...
WORCESTER, Mass. and TORONTO, June 6, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today a podium presentation on the technology and clinical results from the on-going Phase II clinical trial of the AE37 breast cancer vaccine being developed by Generex wholly-owned subsidiary Antigen Express, Inc. The presentation was at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) on June 4, 2012 in...
Agent benefits melanoma and lung cancer as well An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center. The results of an expanded Phase 1 trial presented at the American Society of Clinical Oncology's annual conference in Chicago, showed that some patients treated with a fully human monoclonal antibody developed by...
